NYSE · GMED

GLOBUS MEDICAL Inc.

$80.14 +$3.65 (+4.77%) 1D Market open
Charting by TradingView

Key Metrics

$10.38B
Market cap
17.70×
P/E · TTM
$3.10B
Revenue · TTM
$586.71M
Net income
EPS · TTM $4.20
Dividend yield —
Free cash flow $610.32M
Beta · 1Y 0.88
EBITDA · TTM $939.10M
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 8
    The stock moved -8.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 8

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$10.38B
Enterprise value—
Shares outstanding135.7M
52-wk range$51.79 – $101.40
Avg volume · 20D1.0M
Net cash —
Book value / share$33.86
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNYSE
About GLOBUS MEDICAL Inc.
IPO dateAug 3, 2012
Employees6000

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E17.70
P/S3.35
P/FCF17.01
EV/EBITDA—
EV/Sales—
Graham №$56.55

Profitability

Gross —
Operating 21.2%
Net 18.9%
FCF 19.7%
ROE / ROIC 13.2% · 14.3%

Financial Health

Current ratio4.56
Quick ratio2.95
Debt / equity—
Debt / EBITDA —
Net cash —
Working capital$1.72B

Cash Flow · TTM

Operating CF $778.51M
Capex −$168.19M
Free cash flow $610.32M
Buybacks $110.00M
Dividends paid —
Shareholder yield 1.1%

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

10.5
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$56.55 vs $78.25
Trades 1.4× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings